FLT3 and acute myeloid leukemia: However its association with intensive chemotherapy in AML FLT3 mutated patients has been approved based on the results of a phase III randomized trial, demonstrating a significant improvement of survival in patients receiving standard chemotherapy plus midostaurin compared to chemotherapy and placebo [73].